

#### Mailing Address:

Attn: Jen Laws PO Box 3009 Slidell, LA 70459

#### Chief Executive Officer:

Jen Laws Phone: (313) 333-8534 Fax: (646) 786-3825 Email: jen@tiicann.org

#### Board of Directors:

Darnell Lewis, Chair Riley Johnson, Secretary Dusty Garner, Treasurer

Michelle Anderson Hon. Donna Christensen, MD Kathie Hiers Kim Molnar Judith Montenegro Amanda Pratter Trelvis D. Randolph, Esq Cindy Snyder

### Director Emeritus:

William E. Arnold (in Memoriam) Jeff Coudriet (in Memoriam) Hon. Maurice Hinchey, MC (in Memoriam) Gary R. Rose, JD (in Memoriam)

## National Programs:

340B Action Center

PDAB Action Center

Transgender Leadership in HIV Advocacy

HIV/HCV Co-Infection Watch

# National Groups:

Hepatitis Education, Advocacy & Leadership (HEAL) Group

Industry Advisory Group (IAG)

National ADAP Working Group (NAWG)

February 10, 2025

North Dakota State Assembly Industry, Business and Labor Committee 600 East Boulevard Avenue Bismarck, ND 58505 Via electronic mail

**RE: HB 1473** 

Dear Honorable Chairman Warrey, Vice Chairman Johnson, Vice Chairman Ostlie Members of the North Dakota Industry, Business and Labor Committee, and your respected staff,

The Community Access National Network (CANN) writes in **OPPOSITION** to **HB 1473**, which would expand the federal 340B Drug Pricing Program in North Dakota without sufficient oversight to ensure the program appropriately serves patients, particularly those living with HIV and other chronic health conditions.

The Community Access National Network (CANN) is a 501(c)(3) national nonprofit organization focusing on public policy issues relating to HIV/AIDS and viral hepatitis. CANN's mission is to define, promote, and improve access to healthcare services and support for people living with HIV/AIDS and/or viral hepatitis through advocacy, education, and networking.

While CANN is primarily focused on policy matters affecting access to care for people living with and affected by HIV, we stand in firm support of all people living with chronic and rare diseases and recognize the very reality of those living with multiple health conditions and the necessity of timely, personalized care for every one of those health conditions. The 340B Drug Pricing Program is of profound importance to our community.

On May 28th, 2024, the "340B Affording Care for Communities and Ensuring a Strong Safety-net Act" or "340B ACCESS Act" was unveiled in the United States House of Representatives. The bill represents a careful negotiation between a variety of stakeholders affected by the 340B program, including but not limited to the National Association of Community Health Centers, a trade organization representing pharmaceutical manufacturers, and several patient advocacy organizations. CANN is proud to count ourselves among the members working to find consensus on reforming the 340B drug discount program.

Page Two RE: HB 1473 Febuary 10, 2025 Page Two

**HB 1473** undermines the well-recognized need for reform to align 340B with its original intent because the bill seeks an avenue to <u>expand 340B contract pharmacy arrangements without limitation</u> – particularly, limitations necessary to ensure proper transparency and accountability.

The primary harm of contract pharmacies in the 340B program is that they can divert profits intended for low-income patients by allowing large, for-profit retail pharmacies to capitalize on discounted drug prices, potentially leading to less money being reinvested in patient care and a lack of transparency regarding how the savings are being used; this can be considered an abuse of a program designed to help vulnerable populations access affordable medications.

Similarly, diversion of program benefit from needy communities and into wealthier communities is only further enabled when the program is expanded without sufficient guardrails. Unchecked, 340B has encouraged consolidation, community pharmacy closures, harms rural access, and in an extraordinary example of abuse, been the driving financing force in mismanaged housing programs that have left patients dead.

**HB 1473** poses the potential to exacerbate problems in the 340B program without sufficiently ensuring the expansion actually benefits patients.

If this body seeks to positively impact patient access to care, priority on <u>PBM reform is a must.</u> PBM reform, not unchecked 340B expansion, speaks most directly to patient concerns regarding pharmacy access, benefit design, and medication affordability.

To be clear, CANN supports a strong 340B program. When 340B operates the way it is intended, safety-net providers thrive and vulnerable communities, families, and individuals gain access to healthcare they might otherwise not have. CANN welcomes discussion on instituting appropriate guardrails into legislation that would serve to strengthen the program, shield good stewards, and hold accountable bad actors within the appropriate limitations of state powers associated with this federal program.

Respectfully submitted,

Sincerely, Kalvin Pugh

Director of State Policy, 340B

Community Access National Network (CANN)

----

On behalf of Jen Laws President & CEO Community Access National Network